Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2017 /
The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.17
Views: 1763

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA

Dr Wang speaks with ecancer at the 2017 ASH annual meeting about the phase 2 ACE-LY-004 study, looking at efficacy and safety of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma. 

He describes the changing landscape of B Cell lymphoma management, with research initiatives conducted through the Cancer Moonshot program working towards doubling disease survival, and the impact of successive generations of TKIs.

Click here to read about the FDA approval of acalabrutinib for mantle cell lymphoma.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation